147 related articles for article (PubMed ID: 20228647)
1. Best practices in multiple sclerosis: infusion reactions versus hypersensitivity associated with biologic therapies.
Namey M; Halper J; O'leary S; Beavin J; Bishop C
J Infus Nurs; 2010; 33(2):98-111. PubMed ID: 20228647
[TBL] [Abstract][Full Text] [Related]
2. Allergic and nonallergic delayed infusion reactions during natalizumab therapy.
Hellwig K; Schimrigk S; Fischer M; Haghikia A; Müller T; Chan A; Gold R
Arch Neurol; 2008 May; 65(5):656-8. PubMed ID: 18474743
[TBL] [Abstract][Full Text] [Related]
3. Management and preparedness for infusion and hypersensitivity reactions.
Lenz HJ
Oncologist; 2007 May; 12(5):601-9. PubMed ID: 17522249
[TBL] [Abstract][Full Text] [Related]
4. An approach to natalizumab hypersensitivity: a case series of induction of tolerance.
Camacho-Halili M; George R; Gottesman M; Davis-Lorton M
Mult Scler; 2011 Feb; 17(2):250-3. PubMed ID: 21177321
[TBL] [Abstract][Full Text] [Related]
5. Acute infusion reactions induced by monoclonal antibody therapy.
Maggi E; Vultaggio A; Matucci A
Expert Rev Clin Immunol; 2011 Jan; 7(1):55-63. PubMed ID: 21162650
[TBL] [Abstract][Full Text] [Related]
6. Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies.
Krumbholz M; Pellkofer H; Gold R; Hoffmann LA; Hohlfeld R; Kümpfel T
Arch Neurol; 2007 Sep; 64(9):1331-3. PubMed ID: 17846274
[TBL] [Abstract][Full Text] [Related]
7. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
Rudick RA; Sandrock A
Expert Rev Neurother; 2004 Jul; 4(4):571-80. PubMed ID: 15853576
[TBL] [Abstract][Full Text] [Related]
8. Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis.
Dorsey ER; Thompson JP; Noyes K; Dick AW; Holloway RG; Schwid SR
Neurology; 2007 May; 68(18):1524-8. PubMed ID: 17470756
[TBL] [Abstract][Full Text] [Related]
9. Infusion reactions: diagnosis, assessment, and management.
Vogel WH
Clin J Oncol Nurs; 2010 Apr; 14(2):E10-21. PubMed ID: 20350882
[TBL] [Abstract][Full Text] [Related]
10. Multiple sclerosis: interferon beta for some serious forms.
Prescrire Int; 2007 Dec; 16(92):252-7. PubMed ID: 18092425
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibodies, immunogenicity, and associated infusion reactions.
Cheifetz A; Mayer L
Mt Sinai J Med; 2005 Jul; 72(4):250-6. PubMed ID: 16021319
[TBL] [Abstract][Full Text] [Related]
12. Infusion reactions triggered by monoclonal antibodies treating solid tumors.
Carney PH; Ollom CL
J Infus Nurs; 2008; 31(2):74-83. PubMed ID: 18344767
[TBL] [Abstract][Full Text] [Related]
13. Very late delayed-allergic reaction to natalizumab not associated with neutralizing antibodies.
Killestein J; Jasperse B; Liedorp M; Seewann A; Polman Ch
Mult Scler; 2009 Apr; 15(4):525-6. PubMed ID: 19324985
[No Abstract] [Full Text] [Related]
14. New Drug For Multiple Sclerosis.
Aschenbrenner DS
Am J Nurs; 2017 Jul; 117(7):22. PubMed ID: 28644283
[No Abstract] [Full Text] [Related]
15. Current evidence and therapeutic strategies for multiple sclerosis.
Wingerchuk DM
Semin Neurol; 2008 Feb; 28(1):56-68. PubMed ID: 18256987
[TBL] [Abstract][Full Text] [Related]
16. Diagnosis of melanoma under concomitant natalizumab therapy.
Vavricka BM; Baumberger P; Russmann S; Kullak-Ublick GA
Mult Scler; 2011 Feb; 17(2):255-6. PubMed ID: 21177318
[No Abstract] [Full Text] [Related]
17. Rituximab in relapsing-remitting multiple sclerosis.
Schrijver HM
N Engl J Med; 2008 Jun; 358(24):2645; author reply 2646-7. PubMed ID: 18557177
[No Abstract] [Full Text] [Related]
18. Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemic.
Rath L; Bui MV; Ellis J; Carey J; Baker J; Taylor L; Fernando H; Taylor N; Savage P; Richards J; Zhong M; Kalincik T; Skibina O; Wesselingh R; Nguyen AL; Monif M; Butzkueven H; van der Walt A
Mult Scler Relat Disord; 2021 Jan; 47():102642. PubMed ID: 33321356
[TBL] [Abstract][Full Text] [Related]
19. Severe relapses after the first infusion of natalizumab in active relapsing-remitting multiple sclerosis.
Rinaldi F; Perini P; Calabrese M; Rinaldi L; Gallo P
Mult Scler; 2009 Nov; 15(11):1359-62. PubMed ID: 19812116
[TBL] [Abstract][Full Text] [Related]
20. Natalizumab: new drug. Multiple sclerosis: risky market approval.
Prescrire Int; 2008 Feb; 17(93):7-10. PubMed ID: 18354844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
